Eli Lilly's Tirzepatide, a GLP1 + GIP receptor agonist combination drug, has been approved by India's CDSCO for type 2 diabetes and obesity treatment. It promotes satiety and better glucose absorption, helping to prevent insulin resistance, a precursor to pre-diabetes and diabetes. However, tirzepatide requires a weekly dose of 10–12 milligrams, which may not be sustainable for most people.